Program
durvalumab
Also written as “Durvalumab”, “MEDI4736” and “MEDI4736 (Durvalumab)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Carcinoma, Hepatocellular · Urinary Bladder Neoplasms · Multiple Myeloma, led by 8 companies.
Drug pageDurvalumab: every studyMany companies study it; this page follows only the 100 they lead. All 482 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 8643 open or running | phase 4since May 27, 2020 | Sep 14, 2012 | Nov 30, 2026phase 2 · NCT07081633 |
| Bristol-Myers Squibbits history only | 70 open or running | phase 2since Feb 16, 2016 | Nov 25, 2015 | none ahead |
| AbbVieits history only | 20 open or running | phase 2since Feb 27, 2015 | Feb 27, 2015 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortium | 10 open or running | phase 2since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| Advaxisits history only | 10 open or running | phase 2since Nov 6, 2014 | Nov 6, 2014 | none ahead |
| AGO Researchits history only | 11 open or running | phase 2since Nov 11, 2020 | Nov 11, 2020 | Jan 2028phase 2 · NCT04644289 |
| Boston Scientificits history only | 11 open or running | phase 2since Sep 1, 2021 | Sep 1, 2021 | Jun 2027phase 2 · NCT05063565 |
| Eli Lillyits history only | 10 open or running | phase 1since Oct 7, 2015 | Oct 7, 2015 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo, Jazz Pharmaceuticals Ireland, Biocompatibles UK, Parexel, Apices Soluciones S.L., IQVIA Pty, Myriad Genetic Laboratories, PRA Health Sciences and Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Academic Thoracic Oncology Medical Investigators Consortium only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 22, 2016First study: phase 2 study in Non-Small Cell Lung Cancer NSCLCFirst studyNCT02879617 · 47 enrolled · United States
TargetBeta
“A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
The one study Academic Thoracic Oncology Medical Investigators Consortium leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02879617Non-Small Cell Lung Cancer NSCLC · United States | 2 | Completed | Jun 4, 2022 | 47 |
How it is read
Names in the registry
- “Durvalumab”, 55 entries
- “MEDI4736”, 20 entries
- “durvalumab”, 7 entries
- “MEDI4736 (Durvalumab)”, 3 entries
- “MEDI4736 + tremelimumab”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 29 studies
- Small Cell Lung Carcinoma, 9 studies
- Carcinoma, Hepatocellular, 8 studies
- Urinary Bladder Neoplasms, 5 studies
- Multiple Myeloma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.